Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Prebet

Showing results (41-50 of 99) with videos related to

Pageof 10
Sort By:
Hematology (Amsterdam, Netherlands)|February 28, 2007
Autologous hematopoietic stem cell transplantation for adults with acute myeloid leukemia in complete remission: the Edouard Herriot Hospital experienceAnne-Sophie Michallet, Youcef Chelghoum, Anne Thiebaut, et al.
Leukemia Research|August 20, 2013
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromesThomas Prebet, Thorsten Braun, Odile Beyne-Rauzy, et al.
Cancer|May 2, 2021
A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemiaGautam Borthakur, Olatoyosi Odenike, Ibrahim Aldoss, et al.
British Journal of Haematology|January 4, 2012
Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agentsDavid Sibon, Giovanna Cannas, Fiorenza Baracco, et al.
Genes, Chromosomes & Cancer|August 31, 2012
Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletionAmel Sebaa, Lionel Ades, Fanny Baran-Marzack, et al.
Leukemia & Lymphoma|May 2, 2022
A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemiaThomas Prebet, Aaron D Goldberg, Joseph G Jurcic, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2024
Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance StudyAntonella Poloni, Klas Raaschou-Jensen, Francisca Hernandez Mohedo, et al.
Blood Advances|March 20, 2024
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trialsPau Montesinos, Amir T Fathi, Stéphane de Botton, et al.
British Journal of Haematology|April 10, 2014
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromesAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
British Journal of Haematology|March 29, 2023
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trialDaniel L Menezes, Wendy L See, Alberto Risueño, et al.
Pageof 10

Showing results (41-50 of 99) with videos related to

Sort By:
Pageof 10
Hematology (Amsterdam, Netherlands)|February 28, 2007
Autologous hematopoietic stem cell transplantation for adults with acute myeloid leukemia in complete remission: the Edouard Herriot Hospital experienceAnne-Sophie Michallet, Youcef Chelghoum, Anne Thiebaut, et al.
Leukemia Research|August 20, 2013
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromesThomas Prebet, Thorsten Braun, Odile Beyne-Rauzy, et al.
Cancer|May 2, 2021
A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemiaGautam Borthakur, Olatoyosi Odenike, Ibrahim Aldoss, et al.
British Journal of Haematology|January 4, 2012
Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agentsDavid Sibon, Giovanna Cannas, Fiorenza Baracco, et al.
Genes, Chromosomes & Cancer|August 31, 2012
Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletionAmel Sebaa, Lionel Ades, Fanny Baran-Marzack, et al.
Leukemia & Lymphoma|May 2, 2022
A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemiaThomas Prebet, Aaron D Goldberg, Joseph G Jurcic, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2024
Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance StudyAntonella Poloni, Klas Raaschou-Jensen, Francisca Hernandez Mohedo, et al.
Blood Advances|March 20, 2024
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trialsPau Montesinos, Amir T Fathi, Stéphane de Botton, et al.
British Journal of Haematology|April 10, 2014
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromesAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
British Journal of Haematology|March 29, 2023
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trialDaniel L Menezes, Wendy L See, Alberto Risueño, et al.
Pageof 10